menu
    • menu
    [{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Novan"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"RVL Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"RVL Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Revision Skincare \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Revision Skincare \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Levation Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic-alpha-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Oxymetazoline Hydrochloride

    Menu

    Oxymetazoline Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Levation Pharma

                            India arrow
                            AACR Annual meeting
                            Not Confirmed

                            Levation Pharma

                            India arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis

                            Details : LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharo...

                            Product Name : LEV102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 27, 2023

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EPI Health

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            EPI Health

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Sato Yakuhin Kogyo Co., Ltd

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RH...

                            Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...

                            Product Name : Rhofade

                            Product Type : Other Small Molecule

                            Upfront Cash : $5.0 million

                            December 21, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Sato Yakuhin Kogyo Co., Ltd

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bayer AG

                            Germany arrow
                            AACR Annual meeting
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Thr...

                            Details : Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.

                            Product Name : Afrin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 17, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EPI Health

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            EPI Health

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Novan

                            Deal Size : $51.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novan Acquires EPI Health, a Specialty Dermatology Company

                            Details : Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.

                            Product Name : Rhofade

                            Product Type : Other Small Molecule

                            Upfront Cash : $27.5 million

                            November 03, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Novan

                            Deal Size : $51.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Revision Skincare

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Revision Skincare

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : RVL Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.

                            Details : As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).

                            Product Name : Upneeq

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 30, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : RVL Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RVL Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            RVL Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Athyrium Capital

                            Deal Size : $24.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing

                            Details : The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.

                            Product Name : Upneeq

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 08, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Athyrium Capital

                            Deal Size : $24.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Osmotica Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Osmotica Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Athyrium Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

                            Details : The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.

                            Product Name : Upneeq

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 10, 2021

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Athyrium Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Osmotica Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Osmotica Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Alora Pharmaceuticals

                            Deal Size : $170.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Osmotica Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pha...

                            Details : Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).

                            Product Name : Upneeq

                            Product Type : Other Small Molecule

                            Upfront Cash : $110.0 million

                            June 25, 2021

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Alora Pharmaceuticals

                            Deal Size : $170.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Osmotica Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Osmotica Pharmaceuticals

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq for Acquired Blepharoptosis (Droopy Eyelid) in A...

                            Details : U.S FDA has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, formerly known as RVL-1201, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid that can l...

                            Product Name : Upneeq

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 07, 2020

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Santen Pharmaceutical

                            Japan arrow
                            AACR Annual meeting
                            Not Confirmed

                            Santen Pharmaceutical

                            Japan arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : RVL Pharmaceuticals

                            Deal Size : $89.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Santen and RVL Pharmaceuticals Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201

                            Details : Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.

                            Product Name : Upneeq

                            Product Type : Other Small Molecule

                            Upfront Cash : $25.0 million

                            July 28, 2020

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : RVL Pharmaceuticals

                            Deal Size : $89.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth